tbuckley/cabot-search huggingface dataset:
Abstract 5526: Lymphangiogenesis in regional lymph nodes is an independent prognostic marker in rectal cancer patients after neoadjuvant treatment
Authors: Christiane Jakob, Daniela E. Aust, Gustavo B. Baretton, Kaustubh Datta, Michael H. Muders
Journal: Cancer Research (2012)

Abstract One of the major prognostic factors in rectal cancer is lymph node metastasis. The formation of lymph node metastases is dependent on the existence of a premetastatic niche. An important factor preceding metastasis are lymph vessels which are located in the lymph node. Accordingly, the occurrence of intranodal lymphangiogenesis is thought to indicate distant metastasis and worse prognosis. To evaluate the significance of lymph node lymphangiogenesis, we studied formalin fixed, paraffin embedded adenocarcinomas and regional lymph nodes of 203 rectal cancer patients who were treated with neoadjuvant radiochemotherapy and consecutive surgery. Regional lymph node lymph vessels were detected by immunohistochemistry for podoplanin (D2-40). Our results show that the presence of lymphatic vessels in regional lymph nodes significantly affects the disease-free survival in univariate and multivariate analyses. In contrast, there was no correlation between peritumoral or intratumoral lymph vessel density and prognosis. Indeed, our study demonstrates the importance of lymphangiogenesis in regional lymph nodes after neoadjuvant radiochemotherapy and consecutive surgery as an independent prognostic marker. Staining for intranodal lymphangiogenesis and methods of intravital imaging of lymphangiogenesis and lymphatic flow may be a useful strategy to predict long-term outcome in rectal cancer patients. Furthermore, addition of VEGF-blocking agents to standardized neoadjuvant treatment schemes might be indicated in advanced rectal cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5526. doi:1538-7445.AM2012-5526
P17.11 * COMBINED RADIOTHERAPY(RT) AND CHEMOTHERAPY(CT) WITH TEMOZOLOMIDE(TMZ) CONCOMITANT(CC) AND ADJUVANT(ADJ) IN GLIOBLASTOMA IN TUNISIA(TN): RETROSPECTIVE STUDY ABOUT 37 CASES
Authors: H. Boussen, S. B. Hamba, F. Benna, S. Labidi, M. Afrit, A. Haddaoui, H. Jemel, N. Kchir
Journal: Neuro-Oncology (2014)

OBJECTIVE: To report the epidemiological and clinical characteristics of a TN serie of GBM treated recently by CC RT-CT then adjuvant with TMZ, according to Stupp protocol(NEJM 2005;352:987-996). PATIENTS AND METHODS: Our retrospective bicentric study included 37 cases of histologically confirmed GBM treated between 2006 and 2012 in Abderrahmen Mami hospital (medical oncology ward) and Taoufik Clinic of Tunis. We collected the following data: age, sex, symptoms, histology, investigations, treatment and evolution. RESULTS: We treated 25 males and 12 females (sex-ratio = 2.08) with a median age of 54 years (13-72). GBM was revealed mainly by deficit symptoms (41%). Surgery consisted in a wide resection in 89% of cases, reported as macroscopically complete in 78% of cases. All our patients received a CC CT-RT and 51% Adj TMZ, 22% receiving the 6 planned cycles. With a median follow-up of 12 months, medican survival was 12 months, 4 remained alive with evolutive disease. 1 and 2 year-actuarial survival were respectively of 77.6% and 38.4%. CONCLUSION: GBM patients in Tunisia have lioblastoma is a rare neoplasm with poor prognosis. Their lower median and overall survivals could be explained by the predominance of high risk cases according to neurofunctional VI-VI RPA classification.
Abstract 5215: EZH2-mediated STAT3 activation in glioblastoma
Authors: Eunhee Kim, Dong-Hun Woo, Jeongwu Lee
Journal: Cancer Research (2012)

Abstract Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor despite maximal therapy. Recent studies suggest that GBMs contain highly tumorigenic, stem cell-like cells termed glioblastoma stem cells (GSCs). GSCs significantly contribute to tumor propagation and treatment resistance and thus are critical target for curative therapy in GBMs. These GSCs share a key characteristic of normal stem cells, such as unlimited self-renewal capacity. Maintenance of the stem cell status in normal stem cells is governed by the Polycomb Repressive Complex 2 (PRC2)-mediated transcriptional repression. Enhancer of zeste homolog 2 (EZH2) is the only catalytically active component in PRC2, and it methylates a specific lysine residue of histone 3, resulting in the repressive chromatin structure. Signal transducer and activator of transcription 3 (STAT3) regulates diverse cellular processes and is frequently activated during tumorigenesis. Components of PRC2 are highly expressed in various cancers including GBMs and STAT3 is required for GSCs maintenance. In this study, we investigated the functional interaction between these two oncogenic pathways regulating GSCs phenotype. We show that targeted pharmacologic disruption of EZH2 by the S-adenosylhomocysteine hydrolase inhibitor called 3-deazaneplanocin A (DZNep), or its specific downregulation by short hairpin RNA (shRNA) inhibits STAT3 activity. Furthermore, AKT-mediated EZH2 phosphorylation affects STAT3 activity through STAT3 methylation. We demonstrate that STAT3 bind to EZH2 promoter and inhibition of STAT3 activity by small molecule inhibitor decrease PRC2 protein expression. Targeting of EZH2 and STAT3 by combined treatment with DZNep and STAT3 inhibitor strongly impairs GSCs self-renewal in vitro and decreases markers of neural stem cell multipotency. In addition, shEZH2 transduction + STAT3 inhibitor treatment extend survival of SCID mice with intracranial GSCs than shEZH2 single transduced group. Together, these obtained results strongly suggest the presence of positive feedback activation loop between PRC2 and STAT3 signaling in GSCs and targeting of this activation loop may offer an attractive therapeutic strategy for GBM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5215. doi:1538-7445.AM2012-5215
Use of Ga-68 DOTATATE PET/CT to Confirm Portal Vein Tumor Thrombosis in a Patient With Pancreatic Neuroendocrine Tumor
Authors: Tze Chwan Lim, Eik Hock Tan, Sumbul Zaheer
Journal: Clinical Nuclear Medicine (2011)

A 37-year-old man complained of increasing severity and frequency of abdominal pain over a 2-year period. Initial contrast-enhanced computed tomography of the abdomen demonstrated diffuse enlargement of the pancreas associated with a filling defect in the portal vein, splenomegaly with wedge-shaped peripheral splenic hypodensities and multiple hepatic hypodensities. Findings were suggestive of a pancreatic malignancy complicated by hepatic metastases, splenic infarcts, and portal vein thrombosis. We describe the use of gallium-68 DOTA-DPhe1, Tyr3-octreotate positron emission tomography/computed tomography (Ga-68 DOTATATE PET/CT) in confirming the diagnosis of a pancreatic neuroendocrine tumor with portal vein tumor thrombosis.
P293 OBESITY DEPRESSES THE ANTI-INFLAMMATORY HSP70 PATHWAY CONTRIBUTING TO THE PROGRESSION OF NAFLD IN OBESE PATIENTS
Authors: N.P. Marroni, F.C. Di Naso, H.S. Fillmann, L. Maggioni, A.V. Padoin, R.J. Ramos, C.C. Mottin, R.R. Porto, A.B. Bittencourt, P.I. Homem de Bittencourt
Journal: Journal of Hepatology (2014)
Retinoblastoma Gene Research Takes New Direction
Authors: P. A. Newman
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Retinoblastoma Gene Research Takes New Direction Get access Patricia A. Newman Patricia A. Newman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 17, 2 November 1988, Pages 1360–1362, https://doi.org/10.1093/jnci/80.17.1360-a Published: 02 November 1988
Case 8-1990
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, H.R. Jones, E.P. Richardson
Journal: New England Journal of Medicine (1990)

Presentation of CaseA 45-year-old woman with known Hodgkin's disease was admitted to the hospital after the abrupt onset of "burning" dysesthesias.She was well until six weeks earlier, when a nonproductive cough developed, with occasional subxiphoid pain. An x-ray film of the chest, obtained elsewhere, showed an anterior superior mediastinal mass, and a computed tomographic (CT) scan of the thorax confirmed its presence. Fifteen days before admission the patient first came to this hospital.The patient was a schoolteacher. Her husband and two children were living and well. There was a history of mitral-valve prolapse noted several years earlier. . . .
PWE-133 Oesophageal Varices Screening - Are we Meeting the Guidelines?: Abstract PWE-133 Table 1
Authors: R Bevan, C Parker, K George, S Panter
Journal: Gut (2013)

<h3>Introduction</h3> Oesophageal varices develop and enlarge in cirrhotic patients at a rate of 8% per year and haemorrhage occurs at a rate of 5–15% per annum, causing significant morbidity and mortality. Of the 16,000 deaths/year attributed to cirrhosis, 33% are due to variceal bleeding. Despite improvements in therapy and prophylaxis the mortality from bleeding varices has remained static. Current BSG guidelines recommend screening with OGD at diagnosis and then 1–3 yearly depending on endoscopic findings<sup>1</sup>. <h3>Methods</h3> A retrospective review of clinic letters for all gastroenterologists at STDH from Aug-Oct 2012 was performed. Those eligible for variceal screening i.e. established cirrhosis, decompensated liver disease or evidence of portal hypertension on imaging were identified. Demographic details and liver disease aetiology were recorded. The endoscopy reporting system was reviewed to identify OGDs performed within the last 3 years and the indication for OGD. If an OGD report was absent, the appointment system and case notes were reviewed to establish if the patient refused or failed to attend (FTA) for OGD. Where no evidence of FTA or refusal were found, clinician failure to refer was documented. <h3>Results</h3> 84 eligible patients were identified, 64 (76.2%) had an OGD recorded within the last 3 years. Table 1 shows results according to liver disease aetiology. In the group with a NAFLD/NASH or “other” aetiology, all 16 cases who had not had OGD had not been referred. Of the alcohol aetiology, 7/16 had not been referred for OGD, and 9/16 FTA or were documented to have refused the test. <h3>Conclusion</h3> Three quarters of patients eligible for varices screening have had an OGD within the maximum time frame suggested by the BSG guidelines. However, excluding OGDs performed for acute bleeding or other indications only 45/84 (56.6%) have been appropriately screened. The majority of cases in this audit are secondary to alcoholic liver disease and their high FTA rate reiterates the known difficulties in engaging this group of patients, although numbers are small. This audit suggests a need to improve rates of screening for oesophageal varices; the main reasons suggested by this audit that could be targeted to improve screening rates are appropriate referral by clinicians and reluctance to attend for the test particularly in liver disease secondary to alcohol. <h3>Disclosure of Interest</h3> None Declared. <h3>Reference</h3> Jalan R, Hayes PC. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2000; 46(Suppl 3):iii1-iii15
AB0189 Macrophages polarization in the gut of patients with ankylosing spondylitis
Authors: F. Ciccia, R. Alessandro, A. Rizzo, A. Accardo-Palumbo, G. Guggino, A. Giardina, G. Triolo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Subclinical gut inflammation occurs in patients with Ankylosing Spondylitis (AS) and long term evolution to overt Crohn's disease (CD) has been described in these patients. Gut mucosal macrophages represent the largest pool of tissue macrophages in the body. Different pathways of macrophage activation have been described in humans. <h3>Objectives</h3> To study the macrophages polarization occurring in the inflamed gut of AS patients. <h3>Methods</h3> Twenty two consecutive HLA-B27<sup>+</sup> Ankylosing Spondylitis (AS) patients, 15 Crohn's Disease (CD) patients and 15 normal controls were included in this study. Four AS patients developed an overt CD during the follow-up and were included. Ileal macrophage subsets were characterized by immunohistochemistry and flow cytometry. Quantitative gene expression analysis, by Real Time-PCR of IFN-g, IRF5, IL-4, IL-5, IL-33 and STAT6 was also performed. <h3>Results</h3> CD68<sup>+</sup> macrophages were expanded in both AS and CD patients but not in controls. Inducible nitric synthase (iNOS<sup>+</sup>) macrophages were increased in both AS and CD patients and comprised classical M1 macrophages (iNOS<sup>+</sup>IL-10<sup>-</sup>) and resolution phase macrophages (rMs) (iNOS<sup>+</sup>IL-10<sup>+</sup>). Adaptive immunity, valued through IFN-g expression, was the main M1-polarizing factor in CD whereas innate immune M1 response, valued through IRF-5 induction, predominates in AS. Increased numbers of CD163<sup>+</sup> (M2) macrophages were observed in both AS and CD patients together with increased expression of Th2 cytokines and the Th2 transcription factor STAT6. Unlike in CD, CD14<sup>+</sup> macrophages were virtually absent in the gut of AS patients and controls. On the other hand CD14<sup>+</sup> macrophages were observed to be expanded in the four AS patients that developed CD. <h3>Conclusions</h3> M1, M2 macrophages and rMs expansion was observed in both AS and CD. IL-33 over-expression immunologically characterizes AS gut inflammation. CD14<sup>+</sup> macrophages were observed in CD patients and appear to characterize evolution from subclinical towards clinically evident gut inflammation in AS. <h3>Disclosure of Interest</h3> None Declared
PTH-149 Successful Care for Patients with Chronic Hepatitis B Virus Infection in a Dedicated Drug and Alcohol Addiction Service in East London
Authors: J Kunkel, M Wilkinson, G R Foster
Journal: Gut (2013)

<h3>Introduction</h3> Chronic Hepatitis B Virus (HBV) infection in persons attending drug addiction services has not been studied as thoroughly as infection with Hepatitis C Virus (HCV). The aim of this audit was to assess the number of service users chronically infected with HBV and their relevant co-infections, co-morbidities and access to treatment. <h3>Methods</h3> The Tower Hamlets Specialist Addiction Unit serves the London Borough of Tower Hamlets with a population of more than 200,000. Its Blood Borne Virus Team (BBVT) provides harm reduction healthcare in more than 10 drug and alcohol addiction facilities including outreach sites and neighbouring boroughs. Data on service users chronically infected with HBV was extracted from the service database. <h3>Results</h3> Of 2577 people currently registered with the BBVT 49 (1.9%) have chronic HBV infection with detectable HBs-Antigen. 88% are male, the average age is 40 years and the majority is of non-British origin with large groups of Baltic (18%) and Black/African/Caribbean (20%) ethnicity. 16 patients (33%) are currently injecting drug users (IDU), 13 (27%) formerly IDU. Other reasons for referral are non-injecting drug and alcohol use. 14/49 patients (29%) have psychiatric comorbidities other than drug/alcohol abuse. 22 patients (45%) knew about their infection when they entered the service. 12 patients (24%) have HBe-Antigen-positive and 37 (76%) HBe-Antigen-negative disease. 12/49 patients (24%) have detectable HCV-RNA and can be regarded as co-infected. 3/49 patients (6%) have detectable Hepatitis D Virus (HDV)-RNA. Two patients (4%) are infected with HBV, HCV and HDV. Two patients (4%) have active syphilis co-infection and HIV-co-infection, respectively. 10/49 patients (20%) have been diagnosed with cirrhosis. One patient has undergone resection for HBV-associated hepatocellular carcinoma and has been followed up for 9 years without recurrence. Two patients were infected after documented vaccination against HBV. 7/49 patients (14%) are currently undergoing treatment with a regimen that is effective against HBV. Three patients have cleared HBV, one through treatment and two spontaneously. <h3>Conclusion</h3> Even in a difficult setting where care can be interrupted by incarceration or psychiatric deterioration, successful health care for patients with chronic HBV infection is possible by using outreach facilities and appointment reminders. The community attending drug addiction services has overlapping risk factors and in East London, only a minority of patients chronically infected with HBV are currently injecting drug users. Vaccination against HBV has no 100% protection rate and service users should repeatedly undergo testing for blood borne viruses. <h3>Disclosure of Interest</h3> None Declared.
AB0794 Intra-Articular Injections in Thumb Osteoarthritis. A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: S. Trellu, S. Dadoun, B. Fautrel, L. Gossec
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Intra-articular injections of corticosteroids (CS) or hyaluronic acid (HA) are reported to be efficacious in hip and knee osteoarthritis (OA). In base of thumb OA (rhizarthrosis), information concerning intra-articular injections efficacy is conflicting. <h3>Objectives</h3> To assess efficacy on pain, function and muscular force of intra-articular injections of CS or HA in thumb OA. <h3>Methods</h3> A systematic review of the literature in PUBMED, EMBASE, Cochrane library and congress abstracts was performed until August 2013. All randomised controlled trials (RCTs) reporting the efficacy of HA or corticosteroids or both in thumb OA were selected. Data were collected using a predetermined form. The outcomes were visual analog scale for pain, functional capacity score as available (in percentage of the maximum possible score) and pulp pinch force at 4, 12 and 24 weeks after injection as available. In each trial, the standardized response mean (SRM) was calculated to assess the magnitude of treatment effect. Pooled SRMs were assessed by meta-analysis using the Mantel-Haenszel method. All meta-analyses were carried out with use of random-effects model in case of significant heterogeneity. <h3>Results</h3> 6 RCTs contributed to 3 meta-analyses (HA versus placebo, CS vs placebo and HA vs CS). Among the 390 patients, 169 were treated with HA, 147 with CS and 74 with placebo: mean age 63±2.3 years; 86% were female. The number of injections varied from 1 to 3. In the meta-analysis comparing HA to placebo (2 RCTs, 148 patients), a difference was evidenced on functional capacity at week 12 (SRM -1.14 [-1.69; -0.60]) with no difference on pain. In the meta-analysis comparing CS to placebo (2 RCTs, 164 patients), no difference was evidenced. In the meta-analysis comparing HA to CS (4 RCTs, 304 patients), there was no difference on pain, function and pulp pinch force until week 12. At week 24, pain VAS was significantly lower in CS group (SRM -1.44 [-2.74; -0.14]) and pulp pinch force better in the HA group (SRM -0.75 [-3.87; 1.97]) and there was no difference in function. <h3>Conclusions</h3> This work suggests similar short-term benefits with HA or CS injections in thumb OA whereas at longer-term follow-up, CS may lead to more pain relief and HA lead to higher pulp pinch force. New studies should be performed to confirm these results. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2692
Fibrotic Disorders Associated with Methysergide Therapy for Headache
Authors: John R. Graham, Howard I. Suby, Philip R. LeCompte, Norman L. Sadowsky
Journal: New England Journal of Medicine (1966)

THE development of retroperitoneal fibrosis in 27 patients using methysergide for the prevention of headache is the occasion for this report. Irving Beck, of Providence, Rhode Island, was the first to suggest a possible connection between methysergide and retroperitoneal fibrosis in July, 1961, when this condition developed in 1 of his patients, supplied with this drug by one of us. When a second patient taking methysergide for headache was similarly afflicted in November, 1962, the 2 cases were reported.1 Since then, as of October, 1965, our attention has been directed to a total of 27 patients in whom, while they . . .
Abstract 5009: Analyses of human specimens and knockout mouse model reveal a tumor suppressor function of <i>EphA2</i> in liver
Authors: Hong Guo, Hui Miao, Xin Chen, Hiroshi Iida, Shuichi Kaneko, Bingcheng Wang
Journal: Cancer Research (2010)

Abstract EphA2 kinase is highly expressed in normal mammalian liver, but its functions are poorly defined. Here we show that EphA2 expression was down-regulated in majority of human hepatocellular carcinoma (HCC) from three different populations. In mice, EphA2 deletion led to enhanced susceptibility to hepatocarcinogenesis induced by diethylnitrosamine (DEN) in tumor multiplicity and burden compared with wild type mice. Acute DEN treatment induced EphA2 expression upregulation, concomitant with mitotic arrest in wild type liver. EphA2-null liver displayed significantly increased apoptosis compared with wild type. Further, acute DEN treatment caused substantially elevated Akt and ERK1/2 kinase activities in EphA2-null but not in wild type liver. Ephrin-A1 stimulation inhibited AKT and ERK1/2 and suppressed cell proliferation in vitro. Re-expression of EphA2 fully restored its function. Liver development displayed stable EphA2 expression and kinase activation increase by age coinciding with upregulated ephrin-A1. Human HCC and the mouse model show that EphA2 suppresses hepatocarcinogenesis by facilitating mitotic arrest in response to carcinogenic insults; inhibition of Akt and ERK is one possible mechanism involved in tumor progression. Together, these finding provide a mechanistic link between EphA2 and liver tumor development. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5009.
A SIMPLIFIED TECHNIQUE FOR MEASUREMENT OF BIODISTRIBUTION AND DOSIMETRY OF In-lll MONOCLONAL ANTIBODY (MOAB) BY WHOLE BODY IMAGING.
Authors: Paul H. Brown, Rhonda K. Denney, Fredrick E. Turner, Shakuntala Krishnamurthy, Susan W. Gilbert, James F. Morris, Gerbail T. Krishnamurthy
Journal: Clinical Nuclear Medicine (1987)

Brown, Paul H.; Denney, Rhonda K.; Turner, Fredrick E.; Krishnamurthy, Shakuntala; Gilbert, Susan W.; Morris, James F.; Krishnamurthy, Gerbail T. Author Information